2013 Pinnacle Biologics Predictions

Quote






Eric L replaces Brad as the new VP of Sales, thus becoming Brad's boss. Brad becomes "East Coast Zone Director" and no longer reports to "Where's Waldo" Altman. Guillermo Herrera hires a West Coast and Midwest Coast zone director. The Midwest Zone Director is newly college graduate Carlos Alban Jr. The West Coast Zone Director is offered to another relative from Columbia.
 






Pinnacle sells Photofrin to the British Technology Group. Pinnacle buys FLUTTER® from Aptalis, and "aligns" the price 600%. And the new team hired to sell Flutter will be asked repeatedly if they are better off than they were 6 months ago.
 












I really hope BTG thoroughly do their homework on Pinnacle Biologics and not buy this drug from them...it would be a huge mistake and a poor investment. Photofrin has been poorly management over the last 15 years
 






Photofrin is not an appealing injectable to companies which produce generics. Why BTG or any company would consider purchasing Photofrin is a mystery. Besides, the pending investigation by the FDA for the off-label marketing of the product will make it "damaged goods." Coupled with a history of product mismanagement, you have a product that is a failure. A company is better off purchasing Flutter from Aptalis since the investment and loss would be minimal. My suggestion to interested Photofrin buyers is to first initiate a meeting with the FDA, so that the FDA is assured you will not condone off-label marketing. The FDA will initiate a meeting (investigation) with the buyer should the buyer fail to contact the FDA first. Since most of the sales are coming from off-label utilization, the FDA will keep a close watch on the new company and their marketing strategies. The FDA realizes that any potential buyer will not purchase Photofrin to generate revenue and maximize profits via FDA indications.
 






CONFIRMATION: Photofrin's off-label marketing (MIRF included) and its' companies currently associated with its' sales efforts are on the FDA radar. Purchasing Photofrin will immediately place the buyer on the FDA radar.
 












Being on the FDA radar and being under investigation are two different matters. Being on their radar can lead to an investigation. The FDA is currently researching the leads submitted to their office and the leads provided by cafe pharma. Stay tuned...
 






Pinnacle Biologics inclusion on Cafe Pharma makes for great reading. It gives Guillermo and his little rascals something to do besides plan on how to pay for more off-label PDT cases.
 






I would have never predicted receiving the 2012 Income Tax statement arriving in a timely fashion. A sincere thank you to Pinnacle Biologics for sending this out in January.
 






PB management becomes frusterated with BTG due to their hesitation in purchasing Photofrin. Too much exposure on Cafe Pharma coupled with notifications sent to BTG management, FDA, consumer awareness groups, The NY Times, etc has taken away ALL the negotiating leverage PB had over BTG. PB will sell for much less...nowhere near their 2011 expectation. SUCKERS!!!!
 






Anonymous said:
BTG wants nothing to do with this failed product and incompetent management team.
Click to expand...

This prediction has been fulfilled. Now, Guillermo will attempt to make PDT w/Photofrin appear to be an appealing procedure to other potential suitors (suckers) by expanding the sales force with 6 additonal reps. It is less costly to invest in 6 additional salaries vs investing in clinical studies to achieve FDA approval for the off-label applications, which happens to be this product's primary utilization.
 






Top Bottom
Back
Quote